0001209191-23-051695.txt : 20231003
0001209191-23-051695.hdr.sgml : 20231003
20231003184933
ACCESSION NUMBER: 0001209191-23-051695
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lennon David James
CENTRAL INDEX KEY: 0001995275
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 231305947
MAIL ADDRESS:
STREET 1: C/O AADI BIOSCIENCE, INC.
STREET 2: 17383 SUNSET BLVD, SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aadi Bioscience, Inc.
CENTRAL INDEX KEY: 0001422142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 611547850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
BUSINESS PHONE: 424-473-8055
MAIL ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
FORMER COMPANY:
FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20170316
FORMER COMPANY:
FORMER CONFORMED NAME: ZETA ACQUISITION CORP II
DATE OF NAME CHANGE: 20071227
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-02
0
0001422142
Aadi Bioscience, Inc.
AADI
0001995275
Lennon David James
C/O AADI BIOSCIENCE, INC.
17383 SUNSET BOULEVARD, SUITE A250
PACIFIC PALISADES
CA
90272
1
1
0
0
Chief Executive Officer
0
Restricted Stock Units
2023-10-02
4
A
0
32558
0.00
A
Common Stock
32558
32558
D
Stock Option (right to buy)
0.00
2023-10-02
4
A
0
490000
0.00
A
2033-10-02
Common Stock
490000
490000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest on October 2, 2024.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2023 Inducement Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest one (1) year after the Date of Grant, and one-forty-eighth (1/48th) of the shares subject to the option shall vest monthly thereafter on the same day of the month as the Date of Grant (and if there is no corresponding day, the last day of the month), such that the option will be fully vested and exercisable four (4) years from the Date of Grant. "Date of Grant" shall mean October 2, 2023.
/s/ Stephen Rodin, as Attorney-in-Fact
2023-10-03